Equillium Q1 net loss, profit miss analyst expectations

Equillium

13/05/2026 21:08

Overview

U.S. biotech's Q1 net loss and adjusted EPS missed analyst expectations

Net loss narrowed yr/yr due to lower R&D and G&A expenses

Cash expected to fund planned operations into 2029 after $35 mln private placement

Outlook

Equillium plans to initiate Phase 1 EQ504 study in mid-2026, with data expected six months later

Company expects cash and cash equivalents to fund planned operations into 2029

Result Drivers

LOWER R&D SPENDING - Co said Q1 R&D expenses fell due to wind down of clinical studies in 2025

LOWER ADMINISTRATIVE COSTS - Co attributed lower G&A expenses to reduced legal and professional fees

Company press release: ID:nGNX3Q0zrZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Miss
-$0.06
-$0.04 (6 Analysts)
Q1 Net Income
Miss
-$5.31 mln
-$4.30 mln (6 Analysts)
Q1 Operating Income
Miss
-$5.61 mln
-$4.53 mln (6 Analysts)
Q1 Basic EPS
-$0.06
Q1 Operating Expenses
$5.61 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Equillium Inc is $6.00, about 164.3% above its May 12 closing price of $2.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)